The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).
 
Yi Hu
No Relationships to Disclose
 
Jianhua Chen
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Jinliang Wang
No Relationships to Disclose
 
Junxun Ma
No Relationships to Disclose
 
Tienan Yi
No Relationships to Disclose
 
Shikai Wu
No Relationships to Disclose
 
Xiangdong Zhou
No Relationships to Disclose
 
Xingxing Zhang
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
Dongmei Chen
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
Songhua Fan
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
Michael Shi
Employment - HUTCHMED
Leadership - HUTCHMED
 
Weiguo Su
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED